There are are 4 planned TRIUMPH trials investigating retatrutide's efficacy in treating obesity and its complications: #type2diabetes #cardiovascular disease #osteoarthritis NEW Data drop at #ADA2023: Retatrutide, a triple agonist (GLP1, GIP, glucagon) lost an incredible 24.2% of their body weight, which amounts to 58 lbs
Its given weekly by injection and is often compared to GLP-1s because the effects (and side effects) overlap, but it tends to have stronger A1c reduction and weight loss effects
For further information, we recommend consulting specialized literature or websites
Catherine Abbott and Dr Melissa Pitman (Flinders University of South Australia) for their gift of recombinant human DPP-4 and advice on DPP-4, Prof Dominic Geraghty (University of Tasmania) and Dr Nick Gust (Department of Primary Industries, Parks Water and Environment) for platypus serum, Ms Carlie Sawtell for echidna Gcg PCR analysis, Dr Tasman Daish and Dr Aaron Casey for tissue collection, and the China Scholarships Council and Adelaide University for supporting Chuan He
Endocrinologists viewed their ideal patient as an individual with established cardiovascular disease or high cardiovascular risk, including those with diabetic kidney disease, who are already being treated with more than one oral medication (including either SGLT2is or GLP1-RAs) and an HbA1c level exceeding the established target
Bismuth can cause stools to be quite pasty and dark, which many patients mistake for tarry. The defining medical difference is the odor